Evidence map›Paper›PMID 31404087›Full record

ArticlePloS one2019

Nuclear corepressor SMRT is a strong regulator of body weight independently of its ability to regulate thyroid hormone action.

Hiroaki Shimizu, Yu Lu, Kristen R Vella, Federico Damilano, Inna Astapova, Izuki Amano, Megan Ritter, Molly R Gallop, Anthony N Rosenzweig, Ronald N Cohen and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Targeting the Liver Serine Protease TMPRSS6 Ameliorates Steatosis and Attenuates Fibrosis in Experimental MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hiroaki ShimizuDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0003-3903-2854
Yu LuDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Kristen R VellaDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Federico DamilanoDivision of Cardiology Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Inna AstapovaDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Izuki AmanoDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Megan RitterDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Molly R GallopDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Anthony N RosenzweigDivision of Cardiology Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Ronald N CohenSection of Endocrinology, Diabetes and Metabolism, University of Chicago, Chicago, Illinois, United States of America.
Anthony N HollenbergDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.
Beth Israel Deaconess Medical Center · USMassachusetts General Hospital · USUniversity of Chicago · US

Funding

COREPRESSOR REGULATION OF THYROID HORMONE ACTIONR01DK056123 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI HOLLENBERG, ANTHONY N · 2000 to 2023
$7.6M
INTEGRATED ENDOCRINE &METABOLIC RESEARCH TRAININGT32DK007516 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BARBARA B. KAHN · 1986 to 2026
$6.8M
NIDDK NIH HHS R01 DK056123NIDDK NIH HHS T32 DK007516
6 · The paper itself

Abstract

Silencing Mediator of Retinoid and Thyroid Hormone Receptors (SMRT) and the nuclear receptor co-repressor1 (NCoR1) are paralogs and regulate nuclear receptor (NR) function through the recruitment of a multiprotein complex that includes histone deacetylase activity. Previous genetic strategies which deleted SMRT in a specific tissue or which altered the interaction between SMRT and NRs have suggested that it may regulate adiposity and insulin sensitivity. However, the full role of SMRT in adult mice has been difficult to establish because its complete deletion during embryogenesis is lethal. To elucidate the specific roles of SMRT in mouse target tissues especially in the context of thyroid hormone (TH) signaling, we used a tamoxifen-inducible post-natal disruption strategy. We found that global SMRT deletion causes dramatic obesity even though mice were fed a standard chow diet and exhibited normal food intake. This weight gain was associated with a decrease in energy expenditure. Interestingly, the deletion of SMRT had no effect on TH action in any tissue but did regulate retinoic acid receptor (RAR) function in the liver. We also demonstrate that the deletion of SMRT leads to profound hepatic steatosis in the setting of obesity. This is unlike NCoR1 deletion, which results in hepatic steatosis due to the upregulation of lipogenic gene expression. Taken together, our data demonstrate that SMRT plays a unique and CoR specific role in the regulation of body weight and has no role in TH action. This raises the possibility that additional role of CoRs besides NCoR1 and SMRT may exist to regulate TH action.

Indexed as

AnimalsBlotting, WesternBody WeightCholesterolEchocardiographyEnergy MetabolismGlucose Tolerance TestLipidsLiverMaleMiceMice, Inbred C57BLMice, KnockoutNuclear Receptor Co-Repressor 2Real-Time Polymerase Chain ReactionThyroid HormonesCholesterolLipidsNcor2 protein, mouseNuclear Receptor Co-Repressor 2Thyroid HormonesThyrotropinThyroxineTriglycerides

Identifiers

PMID31404087
PMCPMC6690520
OpenAlexW2968148090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.